Norbert Jorch

Muenster, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Markers and regulators of osteoblast and osteoclast activity in children with X-linked hypophosphatemia treated with burosumab.

Markers and regulators of osteoblast and osteoclast activity in children with X-linked hypophosphatemia treated with burosumab.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Published: October 30, 2025

Anthropometric characteristics at birth and growth outcome in patients with X-linked hypophosphatemia treated with oral phosphate and active vitamin D.

Anthropometric characteristics at birth and growth outcome in patients with X-linked hypophosphatemia treated with oral phosphate and active vitamin D.

Journal: Pediatric nephrology (Berlin, Germany)

Published: September 09, 2025

Approaches to Invasive Fungal Diseases in Paediatric Cancer Centres: An Analysis of Current Practices and Challenges in Germany, Austria and Switzerland.

Approaches to Invasive Fungal Diseases in Paediatric Cancer Centres: An Analysis of Current Practices and Challenges in Germany, Austria and Switzerland.

Journal: Mycoses

Published: April 01, 2025

Growth dynamics of transversal body dimensions and proportions, with related clinical determinants in children with X-linked hypophosphatemia treated with phosphate supplements and active vitamin D.

Growth dynamics of transversal body dimensions and proportions, with related clinical determinants in children with X-linked hypophosphatemia treated with phosphate supplements and active vitamin D.

Journal: Pediatric nephrology (Berlin, Germany)

Published: February 08, 2025

Office Blood Pressure and Obesity in Children with X-Linked Hypophosphatemia.

Office Blood Pressure and Obesity in Children with X-Linked Hypophosphatemia.

Journal: Calcified tissue international

Published: December 11, 2024

MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade glioma.

MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade glioma.

Journal: Acta neuropathologica

Published: November 13, 2024

Distinct pathways for genetic and epigenetic predisposition in familial and bilateral Wilms tumor.

Distinct pathways for genetic and epigenetic predisposition in familial and bilateral Wilms tumor.

Journal: Genome medicine

Published: November 01, 2024

Health-related quality of life of children with X-linked hypophosphatemia in Germany.

Health-related quality of life of children with X-linked hypophosphatemia in Germany.

Journal: Pediatric nephrology (Berlin, Germany)

Published: March 08, 2024

Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial.

Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial.

Journal: The Lancet. Oncology

Published: December 18, 2023

Survival in primary hemophagocytic lymphohistiocytosis, 2016 to 2021: etoposide is better than its reputation.

Survival in primary hemophagocytic lymphohistiocytosis, 2016 to 2021: etoposide is better than its reputation.

Journal: Blood

Published: August 22, 2023

Effects of Burosumab Treatment on Mineral Metabolism in Children and Adolescents With X-linked Hypophosphatemia.

Effects of Burosumab Treatment on Mineral Metabolism in Children and Adolescents With X-linked Hypophosphatemia.

Journal: The Journal of clinical endocrinology and metabolism

Published: November 25, 2022

Amsacrine combined with etoposide and methylprednisolone is a feasible and safe component in first-line intensified treatment of pediatric patients with high-risk acute lymphoblastic leukemia in CoALL08-09 trial.

Amsacrine combined with etoposide and methylprednisolone is a feasible and safe component in first-line intensified treatment of pediatric patients with high-risk acute lymphoblastic leukemia in CoALL08-09 trial.

Journal: Pediatric blood & cancer

Published: May 27, 2022

Showing 1-12 of 32

Last Updated: 09/26/2026